PE20211962A1 - Anticuerpos antiperiostina y usos de estos - Google Patents

Anticuerpos antiperiostina y usos de estos

Info

Publication number
PE20211962A1
PE20211962A1 PE2021000873A PE2021000873A PE20211962A1 PE 20211962 A1 PE20211962 A1 PE 20211962A1 PE 2021000873 A PE2021000873 A PE 2021000873A PE 2021000873 A PE2021000873 A PE 2021000873A PE 20211962 A1 PE20211962 A1 PE 20211962A1
Authority
PE
Peru
Prior art keywords
antibodies
antiperiostin
tumor
increasing
periostin
Prior art date
Application number
PE2021000873A
Other languages
English (en)
Inventor
Arif Jetha
Johan Fransson
Aj Robert Mcgray
Joanne Hulme
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of PE20211962A1 publication Critical patent/PE20211962A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta referido a anticuerpos que inhiben las funciones de la periostina, tales como la union celular mediada por integrina y que son utiles para el tratamiento contra el cancer. Estos anticuerpos antiperiostina disminuyen el contenido de colageno de los tumores y reducen la infiltracion de las poblaciones de celulas mieloides supresoras, tales como las celulas granulociticas y los macrofagos asociados a tumores, mientras que aumentan la polarizacion del macrofago a un fenotipo M1 y aumentan la acumulacion y las propiedades antitumorales de los linfocitos T que infiltran tumores.
PE2021000873A 2018-12-14 2019-12-13 Anticuerpos antiperiostina y usos de estos PE20211962A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779996P 2018-12-14 2018-12-14
US201962899075P 2019-09-11 2019-09-11
PCT/IB2019/001307 WO2020121059A1 (en) 2018-12-14 2019-12-13 Anti-periostin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20211962A1 true PE20211962A1 (es) 2021-10-04

Family

ID=71075443

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000873A PE20211962A1 (es) 2018-12-14 2019-12-13 Anticuerpos antiperiostina y usos de estos

Country Status (21)

Country Link
US (1) US20220010003A1 (es)
EP (1) EP3894439A4 (es)
JP (2) JP2022513228A (es)
KR (1) KR20210108972A (es)
CN (1) CN113631571A (es)
AU (1) AU2019395887A1 (es)
BR (1) BR112021010634A2 (es)
CA (1) CA3120059A1 (es)
CL (1) CL2021001297A1 (es)
CO (1) CO2021007444A2 (es)
CR (1) CR20210310A (es)
DO (1) DOP2021000113A (es)
EC (1) ECSP21043288A (es)
IL (1) IL283890A (es)
JO (1) JOP20210144A1 (es)
MA (1) MA54472A (es)
MX (1) MX2021007043A (es)
PE (1) PE20211962A1 (es)
SA (1) SA521422250B1 (es)
SG (1) SG11202103849TA (es)
WO (1) WO2020121059A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3148291A1 (en) * 2019-09-11 2021-03-18 Boehringer Ingelheim Io Canada, Inc. Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
KR20240038198A (ko) 2022-09-15 2024-03-25 한남대학교 산학협력단 인슐린 분비 베타세포 분화 유도 항체 및 이를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
EP2180007B2 (en) 1998-04-20 2017-08-30 Roche Glycart AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2007096142A2 (en) * 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2757376A4 (en) * 2011-09-15 2015-05-27 Univ Nagoya Nat Univ Corp MOLECULAR MARKER FOR EARLY IDENTIFICATION OF PATIENTS WITH PLEURAL MESOTHELIOMA AND RELATED EXPRESSION ANALYSIS METHOD
JP6218088B2 (ja) * 2013-03-08 2017-11-01 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ−２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
RU2748401C2 (ru) * 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47

Also Published As

Publication number Publication date
EP3894439A4 (en) 2022-11-30
CL2021001297A1 (es) 2022-01-07
MX2021007043A (es) 2021-08-11
CR20210310A (es) 2021-11-24
JP2022513228A (ja) 2022-02-07
US20220010003A1 (en) 2022-01-13
SG11202103849TA (en) 2021-05-28
EP3894439A1 (en) 2021-10-20
CA3120059A1 (en) 2020-06-18
BR112021010634A2 (pt) 2021-11-16
JP2023139243A (ja) 2023-10-03
CO2021007444A2 (es) 2021-09-30
KR20210108972A (ko) 2021-09-03
DOP2021000113A (es) 2021-09-30
AU2019395887A1 (en) 2021-05-20
SA521422250B1 (ar) 2023-12-21
WO2020121059A1 (en) 2020-06-18
ECSP21043288A (es) 2021-09-30
JOP20210144A1 (ar) 2023-01-30
IL283890A (en) 2021-07-29
CN113631571A (zh) 2021-11-09
MA54472A (fr) 2022-03-23

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
UY37621A (es) Arn terapéutico que codifica citoquinas
UY36968A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
MX2021002912A (es) Proteinas de union a cd33 y cd3 biespecificas.
CO2022008728A2 (es) Compuestos y métodos para la degradación dirigida del receptor de andrógenos
CL2017002637A1 (es) Compuestos nucleósidos 5'-sustituidos.
CL2018001052A1 (es) Péptidos y peptidomiméticos en combinación con agentes activadores de células t y/o inhibidores de puntos de control para el tratamiento del cáncer
UY35961A (es) Anticuerpos y fragmentos anti-vista
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
PE20211962A1 (es) Anticuerpos antiperiostina y usos de estos
CL2017003131A1 (es) Terapia de combinación para el tratamiento de cáncer
ECSP15042895A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112018013725A2 (pt) combinações anti-her2 para o tratamento de tumores
DOP2020000116A (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este
MX2021015495A (es) Composiciones y métodos para tratar cáncer.
CO2021006493A2 (es) Terapia del cáncer con células inmunitarias anti-liv1
CO2021005471A2 (es) Terapia del cáncer con células inmunitarias anti-ptk7
CL2023002809A1 (es) Agonistas del receptor de glucocorticoides
CY1123754T1 (el) Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου
ECSP21044672A (es) Anticuerpos agonistas de flt3 y usos de estos
AR113867A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este